Abstract

In this work, we have generated epidermal growth factor receptor (EGFR)-specific cattle-derived ultralong CDR-H3 antibodies by combining cattle immunization with yeast surface display. After immunization, ultralong CDR-H3 regions were specifically amplified and grafted onto an IGHV1-7 scaffold by homologous recombination to facilitate Fab display. Antigen-specific clones were readily obtained by fluorescence-activated cell sorting (FACS) and reformatted as chimeric antibodies. Binning experiments revealed epitope targeting of domains I, II, and IV of EGFR with none of the generated binders competing with Cetuximab, Matuzumab, or EGF for binding to EGFR. Cattle-derived chimeric antibodies were potent in inducing antibody-dependent cell-mediated cytotoxicity (ADCC) against EGFR-overexpressing tumor cells with potencies (EC50 killing) in the picomolar range. Moreover, most of the antibodies were able to significantly inhibit EGFR-mediated downstream signaling. Furthermore, we demonstrate that a minor fraction of CDR-H3 knobs derived from generated antibodies was capable of independently functioning as a paratope facilitating EGFR binding when grafted onto the Fc part of human IgG1. Besides slightly to moderately diminished capacities, these engineered Knobbodies largely retained main properties of their parental antibodies such as cellular binding and triggering of ADCC. Hence, Knobbodies might emerge as promising tools for biotechnological applications upon further optimization.

Highlights

  • Antibody therapeutics have been proven to be of utmost relevance for the treatment of life-threatening conditions, for instance, oncological or infectious diseases and immunological disorders

  • In order to generate epidermal growth factor receptor (EGFR)-specific ultralong CDR-H3 antibodies by yeast surface display following cattle immunization, we developed a strategy that relies on specific ultralong CDR-H3 amplification and subsequent engraftment of this region onto bovine/human chimeric Fab fragments (Figure 1A)

  • Yeast surface display has proven to be versatile for engineering different antibody derivatives [36,37,38,39,40,41] and more complex molecules such as cytokines [42], ligands [43], or cysteine-rich miniproteins [44, 45]

Read more

Summary

Introduction

Antibody therapeutics have been proven to be of utmost relevance for the treatment of life-threatening conditions, for instance, oncological or infectious diseases and immunological disorders. It is projected that by the year 2025, the global antibody sector will be valued 300 billion US dollars [3]. Antibodies will represent one of the main drivers of the pharmaceutical sector. In addition to canonical antibodies composed of heavy and light chains, the adaptive immune system of several species such as camelids or sharks produces non-conventional scaffolds, for instance, heavy-chain only antibodies that display several beneficial attributes with respect to biomedical applications [4,5,6]. Non-immunoglobulin-based humoral components have been identified that respond to foreign antigen in an adaptive manner [7,8,9]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call